Carcinoma ass. Antigen (clone 175F4), anti-human
€564.00
In stock
SKU
ARP-21-5026
Catalog Number: 21-5026
Size: 100 µg
Isotype: Mouse IgG1
Size: 100 µg
Isotype: Mouse IgG1
Background:
The chance of cure and choice of therapy for squamous carcinomas of the head and neck depend largely on the extent of disease, as assessed clinically by inspection,palpation and radiography. Since treatment failures are in part due to clinically undetected metastasis at the time of treatment, there is a need for more specific methods of tumor detection. Attempts to develop antibodies recognizing tumour-associated antigens have, in the case of carcinomas, resulted in the isolation of a large number of antibodies reactive with high-molecular-weight glycoproteins. Monoclonal antibodies (mAbs) 175F4 (IgG1) and 175F11 (IgG2a), originally raised anti the Human mammary carcinoma cell line (ZR-75-1), react with a carcinoma-associated antigen in both adenocarcinomas and squamous cell carcinomas of different origins. Immunohistochemically, the mAbs exhibited reactivity with 42 out of 43 squamous cell carcinomas of the head and neck. Normal squamous epithelia are also reactive with the antibodies in the basal and suprabasal cell layer.
Clone: 175F4
Isotype: Mouse IgG1
Source: 175F4 is a Mouse monoclonal IgG1 antibody derived by fusion of SP2/0 Mouse myeloma cells with spleen cells from a BALB/c Mouse immunized with EDTA treated Human mammary carcinoma cell line (ZR-75-1).
Reactivity: human
Specificity: 175F4, which, originally, has been raised anti the Human mammary carcinoma cell line (ZR-75-1), react with a carcinoma-associated antigen in both adenocarcinomas and squamous cell carcinomas of different origins.
Form: Each vial contains 100ul purified monoclonal antibody in PBS containing 0.09% sodium azide.
Applications: Immunohistochemistry (frozen)
Storage: Store at 4C, or in small aliquots at -20C.
The chance of cure and choice of therapy for squamous carcinomas of the head and neck depend largely on the extent of disease, as assessed clinically by inspection,palpation and radiography. Since treatment failures are in part due to clinically undetected metastasis at the time of treatment, there is a need for more specific methods of tumor detection. Attempts to develop antibodies recognizing tumour-associated antigens have, in the case of carcinomas, resulted in the isolation of a large number of antibodies reactive with high-molecular-weight glycoproteins. Monoclonal antibodies (mAbs) 175F4 (IgG1) and 175F11 (IgG2a), originally raised anti the Human mammary carcinoma cell line (ZR-75-1), react with a carcinoma-associated antigen in both adenocarcinomas and squamous cell carcinomas of different origins. Immunohistochemically, the mAbs exhibited reactivity with 42 out of 43 squamous cell carcinomas of the head and neck. Normal squamous epithelia are also reactive with the antibodies in the basal and suprabasal cell layer.
Clone: 175F4
Isotype: Mouse IgG1
Source: 175F4 is a Mouse monoclonal IgG1 antibody derived by fusion of SP2/0 Mouse myeloma cells with spleen cells from a BALB/c Mouse immunized with EDTA treated Human mammary carcinoma cell line (ZR-75-1).
Reactivity: human
Specificity: 175F4, which, originally, has been raised anti the Human mammary carcinoma cell line (ZR-75-1), react with a carcinoma-associated antigen in both adenocarcinomas and squamous cell carcinomas of different origins.
Form: Each vial contains 100ul purified monoclonal antibody in PBS containing 0.09% sodium azide.
Applications: Immunohistochemistry (frozen)
Storage: Store at 4C, or in small aliquots at -20C.
| Is Featured? | No |
|---|
Write Your Own Review